ArticleFrontiers in pharmacology2025

Cost-effectiveness analysis of gumarontinib versus savolitinib for the treatment of advanced or metastatic NSCLC with MET exon 14 skipping mutations in China using partitioned survival model.

Gang Fang et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.